Journal of Medical Economics
Volume 23, 2020 - Issue 1
Open access
5,457
Views
14
CrossRef citations to date
0
Altmetric
Oncology
Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States
Alison StopeckDivision of Hematology/Oncology, Stony Brook Cancer Center, Stony Brook, NY, USA; Correspondence[email protected]
, Adam BrufskyDivision of Hematology/Oncology, University of Pittsburgh, Pittsburgh, PA, USA;
, Lisa KennedyEpiphany, Los Angeles, CA, USA;
, Sumi BhattaGlobal Health Economics, Amgen Inc, Thousand Oaks, CA, USA
, Debajyoti BhowmikGlobal Health Economics, Amgen Inc, Thousand Oaks, CA, USA
, Jacqueline BuchananGlobal Health Economics, Amgen Inc, Thousand Oaks, CA, USA
, Nicolas DespiegelGlobal Health Economics, Amgen Inc, Thousand Oaks, CA, USA
& Guy HechmatiGlobal Health Economics, Amgen Inc, Thousand Oaks, CA, USA
show all
Pages 37-47
|
Received 17 Jun 2019, Accepted 30 Jul 2019, Published online: 26 Aug 2019
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.